 |
15 Diseases |  |
1 Trial |
|
1 Trial |  |
174 News |  |
| 12» |
- | Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, velpatasvir (GS-5816) / Gilead, voxilaprevir (GS-9857) / Gilead
Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure. (Pubmed Central) - Feb 15, 2024
The study results, derived from a multicenter cohort consisting of 746 patients, demonstrated that re-treatment with VOX/VEL/SOF is an effective salvage therapy associated with an overall per protocol sustained virologic response rate of 95%. Hepatocellular carcinoma onset, cirrhosis and HCV genotype 3 were identified as independent negative predictors of treatment response, whereas resistance-associated substitutions, as well as rare genotypes and chimera, did not impact sustained virologic response rates following re-treatment with VOX/VEL/SOF.
- Sovaldi (sofosbuvir) / Gilead
Sofosbuvir/Viplatasvir/Vosigrivir Retreatment of Hepatitis C Failed a NS5A-containing DAAs Regimen (New Hall) - Jan 6, 2024 - Abstract #APASL2024APASL_561;
The two cases we reported showed the use of Sofosbuvir/Viplatasvir/Vosigrivir combined with or without ribavirin therapy for patients who failed DAA treatment with NS5A inhibitors is effective and well tolerated. This group of cases represents an effective re-treatment program with good curative effects and few side effects.
- | Journal: Recent Methods for the Synthesis of Quinoxaline Derivatives and their Biological Activities. (Pubmed Central) - Oct 27, 2023
Recognizing the significance of these bioactive quinoxaline derivatives, researchers have dedicated their efforts to developing various synthetic methods for their production. This review aimed to compile the most recent findings on the synthesis and biological properties of quinoxaline derivatives from 2015 to 2023.
- | Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, velpatasvir (GS-5816) / Gilead, voxilaprevir (GS-9857) / Gilead
Journal: Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals. (Pubmed Central) - Oct 4, 2023
A comparison of double and triple pangenotypic retherapy in patients after failure of DAA therapy showed a higher sustained virological response in the triple option with a comparable response at the end of therapy. The factors reducing the chances of cure were cirrhosis, genotype 3 infection and male gender.
- | voxilaprevir (GS-9857) / Gilead
Journal: Computational model for lipid binding regions in phospholipase (Ves a 1) from Vespa venom. (Pubmed Central) - Jul 5, 2023
Furthermore, the MD simulation results indicated that voxilaprevir formed stable conformations within the catalytic pocket. Consequently, voxilaprevir could act as a potent inhibitor, opening up avenues for the development of more effective anti-venom therapeutics for Ves a 1.
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, velpatasvir (GS-5816) / Gilead, voxilaprevir (GS-9857) / Gilead
Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients with prior failure to DAA treatment (Strauss 1) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_2375;
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, voxilaprevir (GS-9857) / Gilead, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Real-life effectiveness of voxilaprevir/sofosbuvir/velpatasvir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_824;
Consequently, voxilaprevir could act as a potent inhibitor, opening up avenues for the development of more effective anti-venom therapeutics for Ves a 1. All patients received VOX/SOF/VEL
- Challenges and synthetic opportunities of macrocyclization as a tool for the development of highly selective kinase inhibitors (Room 138 (Indiana Convention Center)) - Feb 14, 2023 - Abstract #ACSSp2023ACS_SP_3836;
Thus, the orthosteric binding pocket of protein kinases is highly conserved and the development of macrocyclic kinase inhibitors is one strategy to overcome this problem. Here I will discuss the challenges and synthetic opportunities for the development of highly selective macrocyclic kinase inhibitors.
- || Review, Journal: A Review on Analytical Strategies for the Assessment of Recently Approved Direct Acting Antiviral Drugs. (Pubmed Central) - Nov 9, 2022
These approaches include spectroscopic, chromatographic, capillary electrophoretic, voltametric and nuclear magnetic resonance methods that have been reported during this period. Moreover, the analytical instrumentation and methods used in determination of these DAADs will be illustrated in tabulated forms.
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, velpatasvir (GS-5816) / Gilead, voxilaprevir (GS-9857) / Gilead
REAL-LIFE EFFECTIVENESS OF VOXILAPREVIR/VELPATASVIR/SOFOSBUVIR IN HEPATITIS C PATIENTS PREVIOUSLY TREATED WITH DIRECT-ACTING ANTIVIRAL AGENTS (DAA) (Room 207) - Oct 23, 2022 - Abstract #AASLD2022AASLD_430;
Patients received VOX/VEL/SOF for 12 weeks, ribavirin was added in 4% of treatment schedules...The most common prior DAA combinations were sofosbuvir plus an NS5A inhibitor (64%) or grazoprevir/elbasvir (12%)... Real-world data show that VOX/VEL/SOF is an effective rescue therapy for patients with prior DAA treatment failure despite the presence of resistance associated substitutions.
- Infrequent hepatitis C genotypes/subtypes in patients treated with DAA-based regimens: successes and failures (Poster Area) - May 12, 2022 - Abstract #EASLILC2022EASL_ILC_2053;
Although the data are limited, these results support the possibility of initially treating them with 2 lastgeneration DAA. More data are needed to determine optimal treatment regimen by genotype/subtype and the benefits of a rational approach based on RAS determination.
- glecaprevir (ABT-493) / AbbVie, velpatasvir (GS-5816) / Gilead, voxilaprevir (GS-9857) / Gilead
Effectiveness of pangenotypic retreatment of HCV infection after prior failure of pangenotypic therapies (Poster Area) - May 12, 2022 - Abstract #EASLILC2022EASL_ILC_1928;
Only men with cirrhosis, infected with genotype 3, did not eliminate HCV infection despite double pangenotypic treatment. We hope to provide data from more patients at the ILC.
- | glecaprevir (ABT-493) / AbbVie, voxilaprevir (GS-9857) / Gilead, BL-8030 / BioLineRx, Genoscience Pharma, Cocrystal Pharma
Journal: Deciphering the Molecular Mechanism of HCV Protease Inhibitor Fluorination as a General Approach to Avoid Drug Resistance. (Pubmed Central) - May 6, 2022
Third generation Hepatitis C virus (HCV) NS3/4A protease inhibitors (PIs), glecaprevir and voxilaprevir, are highly effective across genotypes and against many resistant variants...However, the molecular basis by which fluorination improves potency and resistance profile of HCV NS3/4A PIs is not well understood...Detailed analysis of the co-crystal structures revealed that PIs with fluorinated P4 caps can sample alternate binding conformations that enable adapting to structural changes induced by the D168A substitution. Our results elucidate molecular mechanisms of fluorine-specific inhibitor interactions that can be leveraged in avoiding drug resistance.
- | Preclinical, Journal: In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models. (Pubmed Central) - May 6, 2022
Inhibitory effects of asunaprevir, daclatasvir, grazoprevir, paritaprevir, simeprevir, and voxilaprevir, direct-acting antiviral (DAA) drugs for the treatment of chronic hepatitis C virus (HCV) infection, were evaluated in vitro against a range of clinically important drug transporters...Furthermore, we refined and developed static models to predict complex DDIs with several statins (pitavastatin, rosuvastatin, atorvastatin, and pravastatin) by mechanistically assessing differential inhibitory effects of perpetrator drugs on multiple transporters, such as organic anion transporting polypeptides (OATP1B), breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), organic anion transporter 3 (OAT3), and cytochrome P450 CYP3A enzyme, as they are known to contribute to absorption, distribution, metabolism and excretion (ADME) of above statins...Our studies suggest that mechanistic static model is a promising and useful tool to provide more accurate prediction of the risk and magnitude of DDIs with statins in early drug development and may help to improve the management of clinical DDIs for HCV drugs to ensure effective and safe HCV therapy. GRAPHICAL ABSTRACT.
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, velpatasvir (GS-5816) / Gilead, voxilaprevir (GS-9857) / Gilead
Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with direct-acting antiviral agents (DAA) (Capital Suite 7) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_520;
VOX/VEL/SOF is an effective retreatment for patients with HCV who have failed on a previous DAA course in a real-life setting. We identified HCV GT 3a and HCC as the main predictors of VOX/VEL/SOF failure.
- || velpatasvir (GS-5816) / Gilead, voxilaprevir (GS-9857) / Gilead
Clinical, Journal: Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. (Pubmed Central) - Jan 29, 2022
VOX/VEL/SOF failure was mainly observed in HCV GT3 and GT1a infected patients with cirrhosis and was not associated with specific RASs pattern within NS3, NS5A or NS5B target regions. Rescue treatment with multiple targeted therapies was effective in the majority of patients.
- || velpatasvir (GS-5816) / Gilead, voxilaprevir (GS-9857) / Gilead
Review, Journal: Treatment failure with DAA therapy: importance of resistance. (Pubmed Central) - Jan 29, 2022
For first-line therapy with glecaprevir/pibrentasvir (G/P) or velpatasvir/sofosbuvir (VEL/SOF) no general baseline resistance analysis is required because of the high antiviral activity and high barrier to resistance...Voxilaprevir/velpatasvir/sofosbuvir (VOX/VEL/SOF) is the first choice for the second-line treatment of patients following a previous DAA failure, with rates of viral eradication above 90% irrespective of the presence of resistance-associated substitutions (RASs)...Limited data are available for third-line therapies. Here, independent of RASs profiles treatment with G/P plus SOF or VOX/VEL/SOF with or without ribavirin for 12 to 24 weeks showed promising results and should be administered.
- | grazoprevir (MK-5172) / Merck (MSD), glecaprevir (ABT-493) / AbbVie, voxilaprevir (GS-9857) / Gilead
Journal: Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants. (Pubmed Central) - Nov 17, 2021
Our SAR data and cocrystal structures revealed the interplay between the P2 and P4 groups, which influenced inhibitor binding and the overall resistance profile. Optimizing inhibitor interactions in the S4 pocket led to PIs with excellent antiviral activity against clinically relevant PI-resistant HCV variants and genotype 3, providing potential pan-genotypic inhibitors with improved resistance profiles.
- voxilaprevir (GS-9857) / Gilead, Opdivo (nivolumab) / Ono Pharma, BMS, Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] MINIMAL DRUG-DRUG INTERACTIONS BETWEEN DIRECT- ACTING ANTIVIRALS AND HCC TREATMENTS – A TERRITORY- WIDE COHORT STUDY () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1206;
More data concerning DDI between immunotherapy and DAA would be helpful to guide the best DAA and HCC treatments for the patients . Table .
- | velpatasvir (GS-5816) / Gilead, voxilaprevir (GS-9857) / Gilead
Journal: The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting. (Pubmed Central) - Oct 12, 2021
The first treatment regimen used was a significant predictor to SVR achievement. This study presents alternative treatment regimens for re-treatment of HCV patients in areas with limited resources in the case of non-availability of other regimens as velpatasvir, voxilaprevir, grazoprevir, elbasvir.
- | Journal: Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019. (Pubmed Central) - Sep 1, 2021
As RASs remain common at the failure of DAAs, their identification could play a crucial role in optimizing re-treatment strategies. In Italy RAS prevalence has been decreasing over the years and susceptibility to the latest developed drug combinations is maintained in most cases.
- | glecaprevir (ABT-493) / AbbVie, voxilaprevir (GS-9857) / Gilead
Journal: Synthetic Opportunities and Challenges for Macrocyclic Kinase Inhibitors. (Pubmed Central) - Aug 25, 2021
Therefore, we reviewed the past literature of drug-like macrocycles highlighting reactions that have been successfully used for the macrocyclization. We classified the cyclization reactions by their type, ring-size, yield, and macrocyclization efficiency index.
- | Preclinical, Journal: Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro. (Pubmed Central) - Aug 25, 2021
Acyclic PIs asunaprevir and faldaprevir had ECs of 72 and 23 μM, respectively...Viral suppression was achieved with 3- to 8-fold EC50 boceprevir or 1-fold EC50 simeprevir or grazoprevir, but not boceprevir, in combination with 0.4- to 0.8-fold EC50 remdesivir; these concentrations did not lead to viral suppression in single treatments. This study could inform development and application of protease inhibitors for optimized antiviral treatments of COVID-19.
- || velpatasvir (GS-5816) / Gilead, voxilaprevir (GS-9857) / Gilead
Clinical, Journal: Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. (Pubmed Central) - Aug 20, 2021
Recently, a second-generation protease- and NS5A-inhibitor plus sofosbuvir (voxilaprevir/velpatasvir/sofosbuvir [VOX/VEL/SOF]) was approved for retreatment after DAA failure. No abstract available
- |||||| New trial, Real-world evidence, Real-world: C-DIAMOND: Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C (clinicaltrials.gov) - Jul 7, 2021
P, N=300, Recruiting, Sponsor: Qing XIe
- || voxilaprevir (GS-9857) / Gilead
Clinical, Journal: VIROLOGICAL PATTERNS OF HCV-PATIENTS WITH FAILURE TO THE CURRENT GENERATION DIRECTLY ACTING ANTIVIRALS. (Pubmed Central) - May 20, 2021
No abstract available To our knowledge, this is one of the first real-life studies describing patients who failed the current generation DAAs; the prevalence of RAS was different according to the DAA regimen used, and the efficacy of re-treatment was high.
- velpatasvir (GS-5816) / Gilead, voxilaprevir (GS-9857) / Gilead, Ledipasvir (GS-5885) / Gilead
[VIRTUAL] Transplantation of Hepatitis C Positive Kidney and Pancreas Allografts Into Hepatitis C Naïve Recipients – A Single Center Experience as a Standard of Care () - May 18, 2021 - Abstract #ATC2021ATC_1838;
Early initiation of therapy is important. We found a higher incidence of BK viremia in these patients compared to standard.
- || Clinical, Review, Journal: Direct-Acting Antivirals interactions with opioids, alcohol or illicit drugs in HCV-infected patients. (Pubmed Central) - Mar 24, 2021
Based on pharmacological considerations, neither efficacy loss, nor adverse drug event associated with detrimental interaction are expected with opioids, stimulants, cannabinoids, and ethanol. In summary, our literature review shows that the interaction potential of DAA with most opioids and illicit drugs is limited and should not be a hurdle to the initiate DAA.
- || Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie, voxilaprevir (GS-9857) / Gilead
Clinical, Journal: Two case reports of chronic hepatitis C retreatment (Pubmed Central) - Feb 11, 2021
Two patients, one originally treated with dasabuvir/ombitasvir/paritaprevir/ritonavir and the other with glecaprevir/pibrentasvir, received a triple combination of sofosbuvir, velpatasvir and voxilaprevir for 12 weeks. Following the retreatment, both patients were permanently virus-free.
- | Journal: HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape. (Pubmed Central) - Sep 24, 2020
Following the retreatment, both patients were permanently virus-free. Position-80-substitutions had relatively low fitness cost and the potential to promote HCV escape from clinically relevant PIs in vitro, despite minor impact in classical short-term resistance assays.
- | Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, voxilaprevir (GS-9857) / Gilead
Journal: Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi. (Pubmed Central) - Sep 24, 2020
Furthermore, hepatotoxicity was not observed in Phase 3 clinical trials with voxilaprevir, consistent with our design strategy. Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) is now an approved pan-genotypic treatment option for the most difficult-to-cure individuals who have previously failed direct acting antiviral therapy.
- | Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, voxilaprevir (GS-9857) / Gilead, sofosbuvir/velpatasvir / Generic mfg.
Journal: Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi and Epclusa. (Pubmed Central) - Sep 24, 2020
VEL combined with sofosbuvir (SOF) is Epclusa, an STR with 98% cure-rates for genotype 1-6 HCV infected patients. Addition of the pan-genotypic HCV NS3/4A protease inhibitor voxilaprevir to SOF/VEL is the STR Vosevi, which affords 97% cure-rates for genotype 1-6 HCV patients who have previously failed another treatment regimen.
- voxilaprevir (GS-9857) / Gilead, sofosbuvir/velpatasvir / Generic mfg., Sovaldi (sofosbuvir) / Gilead
[VIRTUAL] Real-world retreatment of HCV-infected patients with prior failure to direct-acting antiviral therapy using sofosbuvir, velpatasvir and voxilaprevir (Channel 5) - Aug 31, 2020 - Abstract #EASLILCI2020EASL-ILC-I-2297;
- | voxilaprevir (GS-9857) / Gilead
Phase classification: Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Aug 21, 2020
P1b, N=101, Completed, Sponsor: Gilead Sciences
Addition of the pan-genotypic HCV NS3/4A protease inhibitor voxilaprevir to SOF/VEL is the STR Vosevi, which affords 97% cure-rates for genotype 1-6 HCV patients who have previously failed another treatment regimen. Phase classification: P1 --> P1b
- || Clinical, Journal: Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa. (Pubmed Central) - Jul 30, 2020
Our outcomes correspond with existing trial and real-world data for similar treatment. DAA therapy and access need rapid upscaling in SA, especially targeting key populations at point of care.
- || Clinical, Journal: Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure. (Pubmed Central) - Jul 18, 2020
Longer treatment duration increased likelihood of SVR. RBV increased likelihood of SVR among patients with GT3, previous DAA TF, or decompensated cirrhosis.
- | Journal: Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. (Pubmed Central) - Jul 5, 2020
Comprehensive PI resistance profiling for HCV genotypes 1-6 revealed 156-RASs as key determinants of high-level resistance across clinically relevant PIs. We obtained in vitro proof-of-concept for persistence of highly fit genotype 1-3 156-variants, which might pose a threat to clinically relevant combination treatments.
- | voxilaprevir (GS-9857) / Gilead
Journal: In vitro Susceptibility of HCV Genotype 1 through 6 Clinical Isolates to the Pan-genotypic NS3/4A Inhibitor Voxilaprevir. (Pubmed Central) - Jun 29, 2020
The majority of RASs known to confer resistance to other protease inhibitors had little to no impact on voxilaprevir susceptibility, except A156L, T or V in genotype 1 to 4 which conferred >100-fold reductions but exhibited low replication capacity in most genotypes. These data support the use of voxilaprevir in combination with other DAAs in DAA-naïve and DAA-experienced patients infected with any subtype of HCV.
- | voxilaprevir (GS-9857) / Gilead
Journal: Correction for Han et al., "In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir". (Pubmed Central) - Jun 27, 2020
These data support the use of voxilaprevir in combination with other DAAs in DAA-naïve and DAA-experienced patients infected with any subtype of HCV. No abstract available
- voxilaprevir (GS-9857) / Gilead
[VIRTUAL] The outcome of re-treatment of relapsed hepatitis C virus infection after direct acting antiviral treatment failure in resource-limited settings (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-793;
In the absence of resistance testing, Sofosbuvir based combinations remain to be effective and safe alternative treatment regimens for retreating hepatitis C virus-infected patients who experienced previous failure of treatment. Additionally, the choice of the first line of treatment has a significant role in treatment response.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie, voxilaprevir (GS-9857) / Gilead
[VIRTUAL] Inadvertent "off label" DAA treatment in the real-world and importance for virologic outcome - data from the German hepatitis C-Registry (DHC-R) (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-785;
Most likely due to simplicity off-label administration of pangenotypic DAA regimen like G/P, VEL/SOF and V/V/S is rare and not associated with reduced SVR rates. Despite frequent inadvertent off-label use for LDV/SOF and GZR/EBR no reduced SVR rates were observed with exception to the use of LDV/SOF in HCV GT 2 and 3.
- [VIRTUAL] Virological characterisation of patients with chronic hepatitis C and failure on glecaprevir/pibrentasvir or voxilaprevir/velpatasvir/sofosbuvir treatment in the international SHARED collaboration (Channel 5) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-138;
After G/P failure, NS5A RASs were frequently observed as dual and triple combination patterns, especially in patients infected by genotypes 3 and 1a. Failure to VVS was mainly observed in patients infected with genotype 3a, with rare occurrence of NS3 and NS5B RASs and a resistance profile of RASs in NS5A that was maintained from previous treatments.
- voxilaprevir (GS-9857) / Gilead
[VIRTUAL] Viremic Hepatitis C (HCV) Donors a Viable Option for Lung Transplant Recipients Treated with Real World Delayed Therapy (Virtual) - May 29, 2020 - Abstract #ATC2020ATC_705;
Delayed HCV treatment was successful, tolerated well and it is a practical approach for these complex patients. Still, further careful characterization of this population is needed.
- || Clinical, Journal: Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report. (Pubmed Central) - May 23, 2020
Still, further careful characterization of this population is needed. The combination of sofosbuvir, glecaprevir/pibrentasvir and ribavirin could be a rescue therapy after previous relapses on DAA-therapy, especially in patients with relapse after therapy with sofosbuvir, velpatasvir, and voxilaprevir.
- || pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie, voxilaprevir (GS-9857) / Gilead
Clinical, Journal: Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures. (Pubmed Central) - Apr 30, 2020
The triple combination of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks is the first-line retreatment strategy in patients previously exposed to DAAs. Difficult-to-retreat patients may benefit from the combination of sofosbuvir plus glecaprevir/pibrentasvir and/or the addition of ribavirin and/or longer retreatment duration.
- ||| velpatasvir (GS-5816) / Gilead, voxilaprevir (GS-9857) / Gilead
I don't check for IBD specifically. I do follow USPSTF screening rec's (once for all 18-79 yo). I do consider testing if additional risk factors (e.g., party animals < 18 or > 79 yo). Velpatasvir and voxilaprevir inhibit BRCP, MTX is substrate. ? significance. (Twitter) - Apr 8, 2020
- || Clinical, Review, Journal: Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatic C virus (HCV). (Pubmed Central) - Mar 4, 2020
While SVR rates have been high, cirrhosis and prior treatment experience marginally compromise response to DAAs. Large scale and exclusive studies in HCV genotype 6 prevalent areas are needed, while the current evidence suggests that DAAs are highly effective and safe.
- || voxilaprevir (GS-9857) / Gilead, Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
Clinical, Journal: A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients. (Pubmed Central) - Feb 9, 2020
P4
Our study demonstrates safety, efficacy and functional benefit of DCV/SOF treatment in KTR with chronic HCV infection. We provide data on rescue strategies for treatment failures due to present RAVs and amelioration of hepatic function and glucose tolerance.
- voxilaprevir (GS-9857) / Gilead, Sovaldi (sofosbuvir) / Gilead
Final challenges: real world experience with sofosbuvir, velpatasvir and voxilaprevir in patients with advanced cirrhosis (Poster Area) - Feb 2, 2020 - Abstract #EASLILC2020EASL-ILC_1170;
- voxilaprevir (GS-9857) / Gilead, Sovaldi (sofosbuvir) / Gilead
Real world retreatment of hcv infected patients with prior failure to direct acting antiviral therapy using sofosbuvir, velpatasvir and voxilaprevir (Poster Area) - Feb 2, 2020 - Abstract #EASLILC2020EASL-ILC_1144;